Second Chance for Moms Act

Summary

Adds a new FDA labeling requirement for the abortion drug mifepristone requiring a conspicuous warning that natural progesterone can counteract mifepristone and may increase the chance of fetal survival, and requires the label to display a toll-free hotline number. Creates a federal, 24/7 toll-free hotline (run by the Department of Health and Human Services directly or via grant/contract) to provide support for people seeking to reverse the effects of mifepristone, with referrals limited to health care providers that offer abortion pill reversal (APR) services. The labeling change takes effect six months after enactment; the bill does not specify an effective date for the hotline beyond directing the Secretary to establish or maintain it.

• Requires mifepristone labeling to include a conspicuous warning that natural progesterone can counteract mifepristone and may increase fetal survival.
• Label must state that the American Society for Reproductive Medicine has determined natural progesterone is safe in the first trimester and include a hotline number.
• Directs the HHS Secretary to establish or maintain a national 24/7 toll-free hotline for people seeking to reverse mifepristone's effects.
• Hotline referrals are limited exclusively to health care providers that offer abortion pill reversal (APR) services.
• Labeling requirement takes effect six months after enactment; the statute does not set a specific start date for the hotline.
• Implementation will require updates by drug manufacturers and action by HHS (operation directly or by grant/contract).
• The bill creates a new federal program duty but does not specify funding amounts or an authorization level for ongoing operations.